Rho-kinase as a drug target for the treatment of airway hyperrespon-siveness in asthma.
In asthma, inflammatory and structural cells contribute to increased bronchoconstriction acutely and more chronically to airway remodelling. Current asthma therapy doesn't inhibit these features satisfactorily. This review discusses Rho-kinase as a potential drug target, since increasing evidence suggests a central role for this pathway in acute and chronic airway hyperresponsiveness.